Maman, Y.; Goykhman, Y.; Yakir, O.; Barenboim, A.; Geva, R.; Peles-Avraham, S.; Wolf, I.; Klausner, J.M.; Lahat, G.; Lubezky, N.
Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Cancers 2023, 15, 3049.
https://doi.org/10.3390/cancers15113049
AMA Style
Maman Y, Goykhman Y, Yakir O, Barenboim A, Geva R, Peles-Avraham S, Wolf I, Klausner JM, Lahat G, Lubezky N.
Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Cancers. 2023; 15(11):3049.
https://doi.org/10.3390/cancers15113049
Chicago/Turabian Style
Maman, Yossi, Yaacov Goykhman, Oz Yakir, Alex Barenboim, Ravit Geva, Sharon Peles-Avraham, Ido Wolf, Joseph M. Klausner, Guy Lahat, and Nir Lubezky.
2023. "Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?" Cancers 15, no. 11: 3049.
https://doi.org/10.3390/cancers15113049
APA Style
Maman, Y., Goykhman, Y., Yakir, O., Barenboim, A., Geva, R., Peles-Avraham, S., Wolf, I., Klausner, J. M., Lahat, G., & Lubezky, N.
(2023). Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Cancers, 15(11), 3049.
https://doi.org/10.3390/cancers15113049
